IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible intravenous infusion pump systems and MRI compatible patient vital signs monitoring systems and related accessories.
FAIL · Does not pass the screen
81.11 USD
Price as of 3 Nov 2026Daily close, not a live quote
Screened 2026-11-03 · the tape above runs as of 16:51 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
Price81.11 USD at the 3 Nov 2026 close
Our value readFair vs our fair value, as of 3 Nov 2026
Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.50, read 2026-10-30
Ethical does not pass the values gate
Price81.11 USD
Fair value85.99
Ethical score70.0/100
Value readFairas of 3 Nov 2026
Our investment reviews on this name
2026-10-11Read Accumulation84.82-4.4% to today Markdown gives way to Accumulation
2026-09-02Read Markdown87.00-6.8% to today ✓Accumulation gives way to Markdown after a 10% slide in 4 weeks
2026-08-02Read Accumulation97.03-16.4% to today Markup gives way to Accumulation with results news in the headlines
2026-07-02Read Markup93.60-13.3% to today First review on file: Markup
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
IRADIMED CORPORATION holds its Distribution at $81.11. Consolidating, no directional conviction, held for 2 days.
As held on the ledger · 2026-11-03
Phase
Distribution · caution
Quantitative state
Consolidating, no directional conviction, held for 2 days
Price at the screen
$81.11
Valuation
48.96 trailing · 35.72 forward price to earnings
Values screen
FAIL· score 70.0
Beta
0.91
The Workings
Five Screens, Shown in Full
Does not pass. Accounts receivable
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
0.00%
Below 33%
Interest-bearing debt is just 0.0% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
59.60%
Below 49%
Money owed to the company is 59.6% of assets, above the 49% limit.
Fail
Revenue purity
2.40%
Below 5%
Only 2.4% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
IRADIMED CORPORATION's business is fine, but its receivables are about 60% of its assets, well over the ~49% line, so it does not pass on the financial screens.
Read as at 2026-11-04. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when IRMD's ethical verdict changes
Today IRMD does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Fair vs our fair value, as of 3 Nov 2026: it trades at roughly an 8% discount to our $85.99 fair value, 0.30% revenue growth.
Fair value range in USD, drawn from the 2026-11-03 screen. The gold marker is the market price at the same screen. A 5.7% discount to the base estimate.
Where our models see it going: fair-value estimate $85.99, with a range of $85.99 to $98.88, dated to the 2026-11-03 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
MRI Pumps Work Well But Trade Too Dear
When an MRI scan needs an IV line most standard pumps must stay outside the room. IRADIMED built the gear that operates safely inside the magnetic field. Yet the shares sit 12 percent above our fair value and carry a forward multiple of 41 times earnings, so we pass.
Revenue is expanding 13 percent a year while margins reach 27 percent and return on equity hits 25 percent. Those figures show a capable niche operator that clears the ethical screen without issue. Still the opportunity rating stays at none because price leaves no margin of safety.
The main risk is paying up for steady but limited growth in a specialised device market. Peak earnings and a stretched multiple often signal a value trap rather than a bargain. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
IRMD trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-30Accumulation$85.82+0.0%Entry 15
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 63%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (2 analysts) rates it none, with a mean price target of $118. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-29Accumulation$85.82-2.1%Entry 14
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 2.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 63%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (2 analysts) rates it none, with a mean price target of $118. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-28Accumulation$87.64+0.0%Entry 13
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 63%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (2 analysts) rates it none, with a mean price target of $118. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-27Accumulation$87.64+0.0%Entry 12
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 63%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (2 analysts) rates it none, with a mean price target of $118. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-26Accumulation$87.64+0.0%Entry 11
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 63%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (2 analysts) rates it none, with a mean price target of $118. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-25Accumulation$87.64+0.0%Entry 10
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 63%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (2 analysts) rates it none, with a mean price target of $118. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-24Accumulation$87.64-2.2%Entry 9
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 2.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 63%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (2 analysts) rates it none, with a mean price target of $118. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-18Accumulation$89.65+5.7%Entry 8
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 5.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 5% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 63%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (2 analysts) rates it none, with a mean price target of $118.
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 2.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 5% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 63%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (2 analysts) rates it none, with a mean price target of $118.
2026-10-02Markdown$82.46-5.2%Entry 6
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 5.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 5% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 63%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (2 analysts) rates it none, with a mean price target of $118.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
